• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 3
  • Tagged with
  • 3
  • 3
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

Familial episodic limb pain in kindreds with novel Nav1.9 mutations / 小児四肢疼痛発作症の家系において新規に同定されたNav1.9遺伝子変異

Kabata, Risako 23 January 2024 (has links)
京都大学 / 新制・論文博士 / 博士(医学) / 乙第13583号 / 論医博第2303号 / 新制||医||1070(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 滝田 順子, 教授 小川 誠司, 教授 松田 文彦 / 学位規則第4条第2項該当 / Doctor of Medical Science / Kyoto University / DFAM
2

The role of the M2C region of the K+ translocating subunit KtrB of the Ktr system of Vibrio alginolyticus

Hänelt, Inga 30 September 2010 (has links)
The KtrAB system of Vibrio alginolyticus is a sodium-dependent potassium transport system. KtrB, the membrane integral and K+ translocating subunit of the KtrAB complex, belongs to a superfamily of K+ transporter (SKT). These proteins are likely to have evolved from simple K+ channels of the M1PM2 type like KcsA by multiple gene duplication and gene fusion. They share a so called fourfold M1PM2-motif, in which two transmembrane helices (M1 and M2) are connected by a p-loop (P), which folds half back into the membrane. Comparing members of this superfamily with the K+ channel KcsA for structural predictions a striking amino acid sequence in helix M2C was found. In VaKtrB the first part of this helix, M2C1, consists of 12 hydrophobic amino acids and is expected to form an α-helix. The following very flexible and hydrophilic part, M2C2, with many glycines and small, partly polar amino acids is not supposed to have a helical conformation. By contrast, the last part, M2C3, shows a partial amphipathic and α-helical character, followed by three positive charged amino acids (R341, K343, K344) which are consistent with the "positive inside rule" and should be localized in the cytoplasm. Due to these findings Durell and Guy in 1999 hypothesised two possible folding models for segments PC and M2C but till now the conformation of this part remains unclear. In this thesis the role of the M2C region was studied in more detail. Point and partial to complete deletions in M2C2 led to a huge increase in Vmax for K+ transport while the affinity for potassium and the sodium transport properties were unaffected. Together with some PhoA-fusion studies which indicated that M2C2 forms a flexible structure within the membrane these data were interpreted to mean that M2C2 forms a flexible gate controlling K+ translocation at the cytoplasmic side of KtrB. This hypothesis was confimed by EPR measurements of single and double spin-labeled cysteine variants of KtrB. It was shown that M2C2 forms a loop inside the cavity of the protein. Upon the addition of K+ ions M2C2 residue T318R1 moved both with respect to M2B residue D222R1 and to M2C3 residue V331, but not with respect to M2C1 residue M311R1. Other residues within M2B, M2C1 and M2C3 did not move with respect to each other. With the help of a rotamer library analysis the measured distances were used to propose two new models for the structure of the M2C2 gate inside the KtrB protein in a closed conformation in the absence of K+ ion and in an open conformation in the presence of K+ ions. Since a flexible gate like M2C2 is missing in potassium channels, it is interpreted to be a transporter-specific structure. In the context of the analysis of the role of M2C2 in purified and reconstituted KtrB by biochemical and biophysical approaches a protocol for the overproduction, purification and reconstitution of natively folded, active protein was developed. In addition, results obtained from static light scattering measurements are shown in order to gain information about the oligomeric state of single subunits as well as of the assembled KtrAB complex.
3

Development of Inhibitors of Human PCSK9 as Potential Regulators of LDL-Receptor and Cholesterol

Alghamdi, Rasha Hassen January 2014 (has links)
Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) is the ninth member of the Ca+2-dependent mammalian proprotein convertase super family of serine endoproteases that is structurally related to the bacterial subtilisin and yeast kexin enzymes. It plays a critical role in the regulation of lipid metabolism and cholesterol homeostasis by binding to and degrading low-density lipoprotein-receptor (LDL-R) which is responsible for the clearance of circulatory LDL-cholesterol from the blood. Owing to this functional property, there is plenty of research interest in the development of functional inhibitors of PCSK9 which may find important biochemical applications as therapeutic agents for lowering plasma LDL-cholesterol. The catalytic domain of PCSK9 binds to the EGF-A domain of LDL-R on the cell surface to form a stable complex and re-routes the receptor from its normal endosomal recycling pathway to the lysosomal compartments leading to its degradation. Owing to these findings, we propose that selected peptides from PCSK9 catalytic domain, particularly its disulphide (S-S) bridged loop1 323-358 and loop2 365-385, are likely to exhibit strong affinity towards the EGF-A domain of LDL-R. Several regular peptides along with corresponding all- dextro and retro-inverse peptides as well as the gain-of-function mutant variants were designed and tested for their regulatory effects towards LDL-R expression and PCSK9-binding in human hepatic HepG2 and mouse hepatic Hepa1c1c7 cells. Our data indicated that disulfide bridged loop1-hPCSK9323-358 and its H357 mutant as well as two short loop2-hPCSK9372-380 and its Y374 mutant peptides modestly promote the LDL-R protein levels. Our study concludes that specific peptides from the PCSK9 catalytic domain can regulate LDL-R and may be useful for development of novel class of therapeutic agents for cholesterol regulation.

Page generated in 0.1275 seconds